Latest Hotspot

Origen Chengdu and Vanotech announce first patient treated with VAN-2201 gene therapy in Phase 1 trial for age-related Wet Macular Degeneration

29 November 2023
3 min read

The initiation of the Phase 1 clinical trial for the VAN-2201 multi-center, conducted jointly by Chengdu Origen Biotechnology Co., Ltd. and Vanotech Ltd., has been declared, signifying that the first patient has been administered with KH631 for the treatment of wet Age-related Macular Degeneration. This clinical trial, which is open-label and involves dose-escalation, will be carried out across various U.S. centers, and is aimed at determining the safety, tolerability, and effectiveness of KH631. This gene therapy will be administered once to previously treated wet AMD patients.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

VEGF The recombinant adeno-associated virus vector, KH631, carries the genetic instructions for a human VEGF receptor fusion protein. Throughout lab-based investigations of models replicating wet AMD, the application of KH631 ensured prolonged retention of the transgene product within the retina and halted disease progression. This may suggest the capability of KH631 to function as a single-dose treatment for patients suffering from wet AMD.

"The initiation of the VAN-2201 Phase 1 trial by administering the therapy to our first patient signifies a significant stride in the progression of KH631. We are probing the viability of a single gene therapy administration as a form of treatment for wet AMD. KH631 is engineered to continuously transport anti-VEGF to the retina, possibly maintaining steady levels that can manage the disease," explained Avner Ingerman, M.D., the top medical officer at Vanotech.

"The chance to partake as a principal investigator in this pivotal investigation thrills me. This first patient dosing signifies a noteworthy progression in the development of an approach utilizing a one-time gene therapy, which could offer hope to patients needing regular treatments for their retinal conditions," said Jeffrey S. Heier, M.D., who serves as principal investigator in the VAN-2201 Phase 1 trial and holds the role of Director of the service offering Vitreoretinal services and also of Retina Research at Boston's Ophthalmic Consultants.

VAN-2201 is basically a Phase 1, multi-center study held in an open-label manner with dose-escalation, centring around patients dealing with wet AMD. The study is set on assessing the safety, tolerance, and effectiveness of a single administration of KH631. The research is projected to involve around twenty-five subjects previously treated for wet AMD who’ve shown to be responsive to anti-VEGF therapy.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 28, 2023, there are 300 investigational drugs for the VEGF target, including 183 indications, 377 R&D institutions involved, with related clinical trials reaching 5147, and as many as 68928 patents.

As KH-631 is currently in Phase 1/2 of development, further clinical trials and research are needed to evaluate its safety and efficacy. However, the use of AAV based gene therapy and the targeting of VEGF show promise in the treatment of congenital disorders and eye diseases. The progress of KH-631 in clinical development will be closely monitored to assess its potential impact on patients suffering from wet AMD and age-related macular degeneration.

图形用户界面, 文本, 应用程序

描述已自动生成

What are IRAK4 inhibitors and how do you quickly get the latest development progress?
What are IRAK4 inhibitors and how do you quickly get the latest development progress?
29 November 2023
IRAK4 inhibitors: Pioneering immune response regulation and promising future in combating hematologic malignancies.
Read →
At the 2023 SNO Conference, Imvax showcased new data supporting its main project, IGV-001, for newly discovered Glioblastoma
Latest Hotspot
3 min read
At the 2023 SNO Conference, Imvax showcased new data supporting its main project, IGV-001, for newly discovered Glioblastoma
29 November 2023
At the 2023 SNO Annual Conference, Imvax displayed novel findings advocating for its principal project, IGV-001, targeting recently identified Glioblastoma.
Read →
An analysis of UCART-22's R&D progress and its clinical results presented at the 2023 ASH Annual Meeting
An analysis of UCART-22's R&D progress and its clinical results presented at the 2023 ASH Annual Meeting
29 November 2023
On 11 Dec 2023, the updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2) in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) will be reported in 2023 ASH.
Read →
HOOKIPA Pharma reveals FDA's approval for their new investigative drug, HB-500, to treat HIV
Latest Hotspot
3 min read
HOOKIPA Pharma reveals FDA's approval for their new investigative drug, HB-500, to treat HIV
29 November 2023
HOOKIPA Pharma Inc. has officially disclosed that the FDA has given the clearance for its IND application for HB-500, This is a new arenaviral therapeutic vaccine designed for HIV treatment.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.